(Adnkronos) - "Oggi è un giorno molto importante perché finalmente fenfluramina è disponibile anche in Italia per la sindrome di Lennox - Gastaut. La fenfluramina riesce a ridurre in modo deciso e duraturo le crisi epilettiche e quindi a contribuire in modo netto a quella che è la qualità di vita del paziente”. Sono le parole di Laura Antonioli, medical affairs head Ucb Italia, alla conferenza stampa organizzata per annunciare il via libera di Aifa alla rimborsabilità di fenfluramina per il trattamento della sindrome di Lennox - Gastaut (Lgs), una grave encefalopatia epilettica e dello sviluppo che colpisce circa un milione di persone in tutto il mondo.
Category
🗞
NewsTranscript
00:00It is a very important day because fenfluramine is finally available also in Italy for the
00:09Lennon-Gastaut syndrome.
00:10It is a very important step because we are talking about a rare pathology in which the
00:15therapeutic outlook is not yet sufficient to meet the needs of these patients, because
00:23they typically speak with resistance.
00:25Fenfluramine is able to reduce epileptic crises in a decisive and long-term way and therefore
00:31to contribute in a clear way to the quality of life of the patient and his family, but
00:36also to the whole picture of the comorbidities that are accompanied in this pathology.
00:44As UCB we do it not only with attention to the molecule and research, but also by supporting
00:52all those initiatives that are around in the life of these patients, therefore favoring
00:58multidisciplinarity, favoring what is the transition from the pediatric age to the
01:04adult age and also an attention to all those that are the social assistance services
01:09that are fundamental in the life of the families of these patients.